Dave Iwanicki
Plus aucun poste en cours
Profil
Dave Iwanicki worked as a Principal at Eli Lilly & Co. He then worked as a Vice President-Sales & Sales Operations at Protein Design Labs, Inc. from 2005 to 2006, and at ESP Pharma, Inc. from 2002 to 2005.
He also worked as a Senior Vice President-Sales at EKR Therapeutics, Inc. and as a Vice President-Sales & Sales Operations at PDL BioPharma, Inc. from 2005 to 2008.
Mr. Iwanicki received his undergraduate degree from Western New England University.
Anciens postes connus de Dave Iwanicki
| Sociétés | Poste | Fin |
|---|---|---|
EKR Therapeutics, Inc.
 EKR Therapeutics, Inc. Hospital/Nursing ManagementHealth Services EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. | Sales & Marketing | 03/10/2012 |
| PDL BIOPHARMA, INC. | Sales & Marketing | 01/03/2008 |
Protein Design Labs, Inc.
 Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Sales & Marketing | 10/01/2006 |
ESP Pharma, Inc.
 ESP Pharma, Inc. Pharmaceuticals: MajorHealth Technology ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ | Sales & Marketing | 01/01/2005 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Formation de Dave Iwanicki
| Western New England University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 4 |
|---|---|
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
ESP Pharma, Inc.
ESP Pharma, Inc. Pharmaceuticals: MajorHealth Technology ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
EKR Therapeutics, Inc.
EKR Therapeutics, Inc. Hospital/Nursing ManagementHealth Services EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. | Health Services |